公开(公告)号：US20230279090A1

公开(公告)日：2023-09-07

申请号：US18301187

申请日：2023-04-14

Applicant: Genentech, Inc. ,  HOFFMANN-LA ROCHE INC.

Inventor： Stefan Dengl ,  Rami Hannoush ,  Simon Theodor Hansen ,  Peter Michael Huelsmann ,  Robert Franklin Kelley ,  Hubert Kettenberger ,  Shrenik Chetan Mehta ,  Devin Brent Tesar

IPC: C07K16/22 ,  C07K14/705 ,  A61P27/02

CPC classification number: C07K16/22 ,  A61P27/02 ,  C07K14/70578 ,  C07K14/70585

Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.

公开(公告)号：US20230256107A1

公开(公告)日：2023-08-17

申请号：US18301180

申请日：2023-04-14

Applicant: Genentech, Inc. ,  HOFFMANN-LA ROCHE INC.

Inventor： Robert Franklin Kelley, JR. ,  Shrenik Chetan Mehta ,  Devin Brent Tesar ,  Rami Hannoush ,  Simon Theodor Hansen ,  Stefan Dengl ,  Hubert Kettenberger ,  Peter Michael Huelsmann

IPC: A61K47/61 ,  A61K47/64 ,  A61K47/68 ,  A61P27/02

CPC classification number: A61K47/61 ,  A61K47/68 ,  A61K47/6425 ,  A61P27/02

Abstract: A conjugate may comprise a first component capable of binding to a therapeutic target in the eye, one or more second component(s) capable of binding to hyaluronan, and one or more third component(s) comprising hyaluronan, wherein each second component is covalently bound to the first component and non-covalently bound to a third component, a composition comprising the conjugate for use as a medicament or for use in the treatment of an eye disease and a method of treating an eye disease in a subject. Additionally, a therapeutic molecule targeted to a tissue in a patient may comprises a hyaluronic acid binding moiety and a therapeutically active agent, wherein the hyaluronic acid binding moiety comprises at least two link domains of Versican.

公开(公告)号：US20230048743A1

公开(公告)日：2023-02-16

申请号：US17811316

申请日：2022-07-08

Applicant: Genentech Inc.

Inventor： Elizabeth Sara Hecht ,  Shrenik Chetan Mehta ,  Wendy Noel Sandoval ,  Sreedhara Alavattam ,  Nathaniel Robert Tzizik-Swanson

IPC: C07K16/40 ,  C12N15/85

Abstract: The present application relates to recombinant antibodies that are engineered to alter interactions between the antibodies and one or more endogenous lipases of a host cell used to produce the antibodies. In some cases, the antibodies are mutated in the heavy chain constant region, such as at CH1, CH2, and/or CH3. In other cases, the antibodies are mutated to alter their glycosylation profile.